Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis

Table 2

Results of RGD PET/CT for four parameters in the diagnosis of suspected carcinoma.

Study	Year	Imaging	SUVmax				SUVmean				T/N				Visual
			TP; (Sen)	FP	FN	TN; (Spe)	TP; (Sen)	FP	FN	TN; (Spe)	TP; (Sen)	FP	FN	TN; (Spe)	TP; (Sen)	FP	FN	TN; (Spe)
Andrei Iagaru	2014	^18F-FPPRGD2 PET/CT	22; (95.7%)	0	1	7; (100%)
Song Gao1	2015	^18F-alfatide RGD PET/CT	17; (100%)	5	0	4; (44.44%)
Song Gao2	2015	^18F-alfatide RGD PET/CT					13 (92.86%)	6	1	132 (95.65%)
Fei Kang1	2015	^68Ga-Alfatide II RGD PET/CT	16; (76.9%)	1	5	12; (90.48%)	18 (84.62%)	3	3	10; (76.19%)					18; (85.71%)	2	3	11; (84.62%)
Fei Kang2	2015	^68Ga-Alfatide II RGD PET/CT	6; (75%)	0	2	9; (100%)
Kun Zheng1	2015	^68Ga-NOTA-PRGD2 PET/CT	55; (80.9%)	4	13	19; (82.6%)	57 (83.8%)	2	11	21; (91.3%)
Kun Zheng2	2015	^68Ga-NOTA-PRGD2 PET/CT	27; (77.14%)	3	8	121; (97.58%)
Yue Zhou	2017	^18F-alfatide RGD PET/CT	18; (90%)	7	2	169; (96%)	17 (85%)	14	3	162; (92.1%)	17; (85%)	7	3	169; (96%)	20; (100%)	9	0	167; (94.9%)
Jiang Wu	2018	^18F-alfatide II RGD PET/CT	37 (88.1%)	5	5	6; (54.5%)	37 (88.1%)	5	5	6; (54.5%)					39; (92.9%)	4	3	7; (63.6%)

Subscript 1: the set of data for the diagnosis of carcinoma in situ. Subscript 2: the set of data for the diagnosis of metastasis. Sen: sensitivity; Spe: specificity. TP: true-positive, FP: false-positive, FN: false-negative, and TN: true-negative.